TW200726766A - Compounds and compositions as protein kinase inhibitors - Google Patents
Compounds and compositions as protein kinase inhibitorsInfo
- Publication number
- TW200726766A TW200726766A TW095116981A TW95116981A TW200726766A TW 200726766 A TW200726766 A TW 200726766A TW 095116981 A TW095116981 A TW 095116981A TW 95116981 A TW95116981 A TW 95116981A TW 200726766 A TW200726766 A TW 200726766A
- Authority
- TW
- Taiwan
- Prior art keywords
- compounds
- raf
- compositions
- protein kinase
- kinase inhibitors
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Transplantation (AREA)
- Rheumatology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Oncology (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US68068405P | 2005-05-13 | 2005-05-13 |
Publications (1)
Publication Number | Publication Date |
---|---|
TW200726766A true TW200726766A (en) | 2007-07-16 |
Family
ID=37074687
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW095116981A TW200726766A (en) | 2005-05-13 | 2006-05-12 | Compounds and compositions as protein kinase inhibitors |
Country Status (19)
Country | Link |
---|---|
US (1) | US8183248B2 (zh) |
EP (1) | EP1891066B1 (zh) |
JP (1) | JP5016593B2 (zh) |
KR (1) | KR20080025039A (zh) |
CN (1) | CN101175753B (zh) |
AR (1) | AR056346A1 (zh) |
AT (1) | ATE492545T1 (zh) |
AU (1) | AU2006247757B2 (zh) |
BR (1) | BRPI0610278A2 (zh) |
CA (1) | CA2607299C (zh) |
DE (1) | DE602006019088D1 (zh) |
ES (1) | ES2358344T3 (zh) |
GT (1) | GT200600197A (zh) |
MX (1) | MX2007014066A (zh) |
PE (1) | PE20061366A1 (zh) |
PL (1) | PL1891066T3 (zh) |
RU (1) | RU2411242C2 (zh) |
TW (1) | TW200726766A (zh) |
WO (1) | WO2006124462A2 (zh) |
Families Citing this family (57)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007053343A2 (en) * | 2005-10-28 | 2007-05-10 | Irm Llc | Compounds and compositions as protein kinase inhibitors |
CN102887900B (zh) | 2006-09-22 | 2015-04-29 | 药品循环公司 | 布鲁顿酪氨酸激酶的抑制剂 |
US20120101114A1 (en) | 2007-03-28 | 2012-04-26 | Pharmacyclics, Inc. | Inhibitors of bruton's tyrosine kinase |
SG10201508035TA (en) * | 2007-03-28 | 2015-10-29 | Pharmacyclics Inc | Inhibitors of bruton's tyrosine kinase |
EP2070929A1 (en) | 2007-12-11 | 2009-06-17 | Bayer Schering Pharma Aktiengesellschaft | Alkynylaryl compounds and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same |
WO2009111280A1 (en) * | 2008-02-29 | 2009-09-11 | Array Biopharma Inc. | N- (6-aminopyridin-3-yl) -3- (sulfonamido) benzamide derivatives as b-raf inhibitors for the treatment of cancer |
CA2716947A1 (en) * | 2008-02-29 | 2009-09-11 | Array Biopharma Inc. | Imidazo [4,5-b] pyridine derivatives used as raf inhibitors |
CN102015707A (zh) * | 2008-02-29 | 2011-04-13 | 阵列生物制药公司 | Raf抑制剂化合物及其使用方法 |
CL2009000448A1 (es) * | 2008-02-29 | 2009-11-27 | Genentech Inc | Compuestos derivados de 3-sulfonilamino-n-(1h-pirazolo-[3,4-b]piridin-5il)benzamida; procesos de preparacion; compuestos intermediarios; composicion farmaceutica; y uso para el tratamiento del cancer, tal como sarcoma, carcinoma, adenoma, entre otros. |
US9273077B2 (en) | 2008-05-21 | 2016-03-01 | Ariad Pharmaceuticals, Inc. | Phosphorus derivatives as kinase inhibitors |
SI2300013T1 (en) | 2008-05-21 | 2018-03-30 | Adriad Pharmacaceuticals, Inc. | Phosphorus derivatives as kinase inhibitors |
EP2671891A3 (en) | 2008-06-27 | 2014-03-05 | Amgen Inc. | Ang-2 inhibition to treat multiple sclerosis |
EP3311818A3 (en) | 2008-07-16 | 2018-07-18 | Pharmacyclics, LLC | Inhibitors of bruton's tyrosine kinase for the treatment of solid tumors |
WO2011109593A1 (en) * | 2010-03-03 | 2011-09-09 | OSI Pharmaceuticals, LLC | Substituted-5-aminopyrrolo/pyrazolopyridines |
EA031737B1 (ru) | 2010-06-03 | 2019-02-28 | Фармасайкликс, Инк. | Применение ингибиторов тирозинкиназы брутона (btk) для лечения лейкоза и лимфомы |
WO2012088266A2 (en) | 2010-12-22 | 2012-06-28 | Incyte Corporation | Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3 |
EP2704572B1 (en) | 2011-05-04 | 2015-12-30 | Ariad Pharmaceuticals, Inc. | Compounds for inhibiting cell proliferation in egfr-driven cancers |
BR112014000314A2 (pt) | 2011-07-08 | 2017-01-10 | Novartis Ag | derivados de pirrolo pirimidina |
JP2014520863A (ja) | 2011-07-13 | 2014-08-25 | ファーマサイクリックス,インク. | Bruton型チロシンキナーゼの阻害剤 |
US9782406B2 (en) | 2011-10-25 | 2017-10-10 | Peking University Shenzhen Graduate School | Kinase inhibitor and method for treatment of related diseases |
CN103073508B (zh) * | 2011-10-25 | 2016-06-01 | 北京大学深圳研究生院 | 激酶抑制剂及治疗相关疾病的方法 |
BR112014015549A8 (pt) * | 2011-12-22 | 2017-07-04 | Hoffmann La Roche | composto, método de inibição da atividade pak1, método para o tratamento, processo, composição, utilização de um composto e invenção |
US8377946B1 (en) | 2011-12-30 | 2013-02-19 | Pharmacyclics, Inc. | Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors |
US20150166591A1 (en) | 2012-05-05 | 2015-06-18 | Ariad Pharmaceuticals, Inc. | Methods and compositions for raf kinase mediated diseases |
CA2875986C (en) | 2012-06-04 | 2020-06-09 | Pharmacyclics, Inc. | Crystalline forms of a bruton's tyrosine kinase inhibitor |
SG11201408238WA (en) | 2012-06-13 | 2015-01-29 | Incyte Corp | Substituted tricyclic compounds as fgfr inhibitors |
WO2014018567A1 (en) | 2012-07-24 | 2014-01-30 | Pharmacyclics, Inc. | Mutations associated with resistance to inhibitors of bruton's tyrosine kinase (btk) |
US9388185B2 (en) | 2012-08-10 | 2016-07-12 | Incyte Holdings Corporation | Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors |
EP2920180A4 (en) | 2012-11-15 | 2016-04-13 | Pharmacyclics Inc | PYRROLOPYRIMIDINE COMPOUNDS AS KINASE INHIBITORS |
US9266892B2 (en) | 2012-12-19 | 2016-02-23 | Incyte Holdings Corporation | Fused pyrazoles as FGFR inhibitors |
WO2014145576A2 (en) | 2013-03-15 | 2014-09-18 | Northwestern University | Substituted pyrrolo(2,3-d)pyrimidines for the treatment of cancer |
US9611283B1 (en) | 2013-04-10 | 2017-04-04 | Ariad Pharmaceuticals, Inc. | Methods for inhibiting cell proliferation in ALK-driven cancers |
EA035095B1 (ru) | 2013-04-19 | 2020-04-27 | Инсайт Холдингс Корпорейшн | Бициклические гетероциклы в качестве ингибиторов fgfr |
US9421208B2 (en) | 2013-08-02 | 2016-08-23 | Pharmacyclics Llc | Methods for the treatment of solid tumors |
JP6429292B2 (ja) | 2013-08-12 | 2018-11-28 | ファーマサイクリックス エルエルシー | Her2増幅性癌の処置のための方法 |
CA2925124A1 (en) | 2013-09-30 | 2015-04-02 | Pharmacyclics Llc | Inhibitors of bruton's tyrosine kinase |
EP3119910A4 (en) | 2014-03-20 | 2018-02-21 | Pharmacyclics LLC | Phospholipase c gamma 2 and resistance associated mutations |
CA2959602A1 (en) | 2014-08-01 | 2016-02-04 | Pharmacyclics Llc | Inhibitors of bruton's tyrosine kinase |
US9545407B2 (en) | 2014-08-07 | 2017-01-17 | Pharmacyclics Llc | Formulations of a bruton's tyrosine kinase inhibitor |
US10851105B2 (en) | 2014-10-22 | 2020-12-01 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
MA41551A (fr) | 2015-02-20 | 2017-12-26 | Incyte Corp | Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4 |
CR20170390A (es) | 2015-02-20 | 2017-10-23 | Incyte Holdings Corp | Heterociclos biciclicos como inhibidores de fgfr |
US9580423B2 (en) | 2015-02-20 | 2017-02-28 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
MD3265084T2 (ro) | 2015-03-03 | 2024-05-31 | Pharmacyclics Llc | Formulări farmaceutice ale inhibitorului tirozin kinazei Bruton |
CN105801584B (zh) * | 2016-03-16 | 2019-03-05 | 中国药科大学 | 新型芳酰胺类Raf激酶抑制剂及其制备方法和用途 |
AR111960A1 (es) | 2017-05-26 | 2019-09-04 | Incyte Corp | Formas cristalinas de un inhibidor de fgfr y procesos para su preparación |
SG11202010636VA (en) | 2018-05-04 | 2020-11-27 | Incyte Corp | Solid forms of an fgfr inhibitor and processes for preparing the same |
WO2019213506A1 (en) | 2018-05-04 | 2019-11-07 | Incyte Corporation | Salts of an fgfr inhibitor |
CN109374896A (zh) * | 2018-11-22 | 2019-02-22 | 中山大学孙逸仙纪念医院 | Plk3前列腺癌预后诊断检测试剂及其试剂盒 |
US11628162B2 (en) | 2019-03-08 | 2023-04-18 | Incyte Corporation | Methods of treating cancer with an FGFR inhibitor |
WO2021007269A1 (en) | 2019-07-09 | 2021-01-14 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
CR20220169A (es) | 2019-10-14 | 2022-10-27 | Incyte Corp | Heterociclos bicíclicos como inhibidores de fgfr |
WO2021076728A1 (en) | 2019-10-16 | 2021-04-22 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
JP2023505258A (ja) | 2019-12-04 | 2023-02-08 | インサイト・コーポレイション | Fgfr阻害剤としての三環式複素環 |
CA3162010A1 (en) | 2019-12-04 | 2021-06-10 | Incyte Corporation | Derivatives of an fgfr inhibitor |
US12012409B2 (en) | 2020-01-15 | 2024-06-18 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
CA3220274A1 (en) | 2021-06-09 | 2022-12-15 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PA8474101A1 (es) | 1998-06-19 | 2000-09-29 | Pfizer Prod Inc | Compuestos de pirrolo [2,3-d] pirimidina |
ID26698A (id) | 1998-06-19 | 2001-02-01 | Pfizer Prod Inc | SENYAWA-SENYAWA PIROLO [2,3-d] PIRIMIDINA |
SK287188B6 (sk) | 1999-12-10 | 2010-02-08 | Pfizer Products Inc. | Pyrolo [2,3-d]pyrimidínová zlúčenina, jej použitie a farmaceutická kompozícia alebo kombinácia s jej obsahom |
SI1294724T1 (sl) | 2000-06-26 | 2006-08-31 | Pfizer Prod Inc | Pirolo(2,3-d)primidinske spojine kot imunosupresivna sredstva |
US20050124637A1 (en) * | 2003-08-15 | 2005-06-09 | Irm Llc | Compounds and compositions as inhibitors of receptor tyrosine kinase activity |
US7338957B2 (en) * | 2003-08-28 | 2008-03-04 | Irm Llc | Compounds and compositions as protein kinase inhibitors |
GB0512324D0 (en) * | 2005-06-16 | 2005-07-27 | Novartis Ag | Organic compounds |
-
2006
- 2006-05-10 KR KR1020077026230A patent/KR20080025039A/ko not_active Application Discontinuation
- 2006-05-10 WO PCT/US2006/018096 patent/WO2006124462A2/en active Application Filing
- 2006-05-10 ES ES06752481T patent/ES2358344T3/es active Active
- 2006-05-10 RU RU2007145935/04A patent/RU2411242C2/ru not_active IP Right Cessation
- 2006-05-10 PL PL06752481T patent/PL1891066T3/pl unknown
- 2006-05-10 AU AU2006247757A patent/AU2006247757B2/en not_active Ceased
- 2006-05-10 MX MX2007014066A patent/MX2007014066A/es active IP Right Grant
- 2006-05-10 DE DE602006019088T patent/DE602006019088D1/de active Active
- 2006-05-10 BR BRPI0610278-6A patent/BRPI0610278A2/pt not_active IP Right Cessation
- 2006-05-10 CA CA2607299A patent/CA2607299C/en not_active Expired - Fee Related
- 2006-05-10 EP EP06752481A patent/EP1891066B1/en not_active Not-in-force
- 2006-05-10 JP JP2008511323A patent/JP5016593B2/ja not_active Expired - Fee Related
- 2006-05-10 AT AT06752481T patent/ATE492545T1/de active
- 2006-05-10 US US11/914,308 patent/US8183248B2/en not_active Expired - Fee Related
- 2006-05-10 GT GT200600197A patent/GT200600197A/es unknown
- 2006-05-10 CN CN2006800161327A patent/CN101175753B/zh not_active Expired - Fee Related
- 2006-05-11 PE PE2006000501A patent/PE20061366A1/es not_active Application Discontinuation
- 2006-05-11 AR ARP060101900A patent/AR056346A1/es unknown
- 2006-05-12 TW TW095116981A patent/TW200726766A/zh unknown
Also Published As
Publication number | Publication date |
---|---|
JP2008540556A (ja) | 2008-11-20 |
BRPI0610278A2 (pt) | 2010-06-08 |
AR056346A1 (es) | 2007-10-03 |
DE602006019088D1 (de) | 2011-02-03 |
WO2006124462A3 (en) | 2007-01-04 |
MX2007014066A (es) | 2008-02-11 |
AU2006247757B2 (en) | 2009-08-27 |
RU2411242C2 (ru) | 2011-02-10 |
PE20061366A1 (es) | 2007-01-05 |
GT200600197A (es) | 2007-03-28 |
PL1891066T3 (pl) | 2011-05-31 |
CA2607299A1 (en) | 2006-11-23 |
RU2007145935A (ru) | 2009-06-20 |
AU2006247757A1 (en) | 2006-11-23 |
CA2607299C (en) | 2013-05-07 |
EP1891066A2 (en) | 2008-02-27 |
EP1891066B1 (en) | 2010-12-22 |
ATE492545T1 (de) | 2011-01-15 |
CN101175753A (zh) | 2008-05-07 |
ES2358344T3 (es) | 2011-05-09 |
CN101175753B (zh) | 2011-03-23 |
US20090118273A1 (en) | 2009-05-07 |
US8183248B2 (en) | 2012-05-22 |
KR20080025039A (ko) | 2008-03-19 |
WO2006124462A2 (en) | 2006-11-23 |
JP5016593B2 (ja) | 2012-09-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TW200726766A (en) | Compounds and compositions as protein kinase inhibitors | |
MX2008001969A (es) | Compuestos y composiciones como inhibidores de proteina cinasa. | |
WO2006101783A3 (en) | Compounds and compositions as protein kinase inhibitors | |
WO2006124731A3 (en) | Compounds and compositions as protein kinase inhibitors | |
WO2007053343A3 (en) | Compounds and compositions as protein kinase inhibitors | |
MX2009003649A (es) | Inhibidores de cinasa de proteina y metodos para utilizarlos. | |
TNSN07176A1 (en) | Compounds and compositions as protein kinase inhibitors | |
TNSN06406A1 (en) | Compounds and compositions as protein kinase inhibitors | |
MX2008001605A (es) | Compuestos y composiciones de tiazol-2-il amino 5-substituido como inhibidores de cinasa proteica. | |
WO2007136465A3 (en) | Compositions and methods for fgf receptor kinases inhibitors | |
EA200901654A1 (ru) | Ингибиторы и способы с их использованием | |
EA201000325A1 (ru) | Производные 2-гетероариламинопиримидина в качестве ингибиторов киназ | |
WO2007134259A3 (en) | Compounds and compositions as protein kinase inhibitors | |
TN2009000145A1 (en) | Compositions and methods for modulating c-kit and pdgfr receptors | |
DE602006014540D1 (en) | Pyrrolopyridinderivate als proteinkinaseinhibitoren | |
EA201000003A1 (ru) | Ингибиторы протеинкиназ и способы их применения | |
WO2007056151A3 (en) | Protein kinase inhbitors | |
WO2005034869A3 (en) | Compounds and compositions as protein kinase inhibitors | |
WO2005039486A3 (en) | Compounds and compositions as protein kinase inhibitors |